EBOS 2022 Full Year Results
24/08/2022
EBOS’ STRONG PERFORMANCE HAS CONTINUED WITH ANOTHER RECORD RESULT AND DOUBLE-DIGIT EARNINGS GROWTH
Full Year Highlights
- Revenue of $10.7 billion, exceeding $10 billion for the first time (up 16.6%)
- Underlying Net Profit after Tax (“Underlying NPAT”) of $228.2 million (up 21.3%)
- $25.6 million of M&A transaction costs (post-tax) were incurred in Statutory NPAT
- Final dividend declared of NZ 49.0 cents per share, bringing total dividends declared for the year to NZ 96.0 cents per share (up 8.5%)
- Continued strong performances from both our Healthcare and Animal Care segments, with Healthcare’s Underlying EBIT up 24.0% and Animal Care’s EBIT up 15.3%
- Underlying operating cash flow (before capex) of $291.0 million (down 3.7%) reflecting higher investment in working capital and tax payments
- Consistent with our strategy of investing for growth, in FY22 we: o continued to invest in our operational infrastructure across the Group to support the growth in the business; and
- completed five acquisitions in a further expansion of our Institutional Healthcare division, including the material acquisition of LifeHealthcare which establishes EBOS as one of the largest independent medical device distributors in Australia, New Zealand and Southeast Asia
- LifeHealthcare performed in line with expectations during June 2022, the first month under EBOS’ ownership, contributing $9.5 million of EBITDA
- Net Debt : EBITDA of 1.94x (0.85x at June 2021), reflecting our recent investments and remaining within the Group’s target gearing range
